Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Iovance Biotherapeutics, Inc. (IOVA)
USD4.36
+0.43 (+10.94%)
US NASDAQ Healthcare Biotechnology
Address
825 Industrial Road 94070
San Carlos, CA, US
San Carlos, CA, US
CEO
Frederick G. Vogt
Website
iovance.com
IPO
2010-10-15
CIK 1425205 ISIN US4622601007
Also trades on
London Stock Exchange · 0JDK.L (USD)
NASDAQ Global Market · IOVA (USD)
Description
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
News Sentiment (7d)
Based on only 2 articles — low confidence
- Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
- This Stock Is Up 74% This Year: Is It Too Late to Buy? Fool - Investing News
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.36
+0.43 (+10.94%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
15M
Beta
0.69
Float Shares
299.84M
Free Float %
83.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.78% | +1.42% | -3.78% | +41.27% | +40.16% | +30.40% | +84.46% | -52.34% | -86.35% | -27.35% | -96.76% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (20 ratings, all time)
Buy
Price Targets & DCF
Current price
4.36
Low
2.00
-54.1%
Consensus
2.00
-54.1%
Median
2.00
-54.1%
High
2.00
-54.1%
DCF (Unlevered)
4.31
-1.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
73% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 6 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 2 |
2.00
-54.1%
|
| All Time | 21 |
15.57
+257.1%
|
Quality scores
Altman Z-Score
-0.98
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+60.6% ★ Q1'26: +44.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+14.8% Q1'26: +47.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-156.8% Q1'26: -110.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-149.2% Q1'26: -113.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-87.3% Q1'26: -70.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+23.3% Q1'26: +29.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.14× Q1'26: -0.16× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 6 EPS Ana. |
Dec 2027 7 Rev. Ana. 5 EPS Ana. |
Dec 2028 7 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 6 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 34.49M (-100.0%)
|
—
est: 238.0K (-100.0%)
|
1.19M
est: 32.77M (-96.4%)
|
164.07M
est: 162.47M (+1.0%)
|
263.50M
est: 257.73M (+2.2%)
|
364.00M
324.62M – 417.87M
+41.2% YoY
|
518.13M
461.43M – 592.18M
+42.3% YoY
|
726.84M
721.24M – 732.45M
+40.3% YoY
|
891.30M
789.89M – 1.05B
+22.6% YoY
|
1.05B
930.17M – 1.24B
+17.8% YoY
|
| EBITDA |
-260.80M
est: -265.44M (+1.7%)
|
-377.74M
est: 47.6K (-793,694.4%)
|
-427.43M
est: -6.55M (-6,421.3%)
|
-351.67M
est: -32.49M (-982.2%)
|
-357.11M
est: -51.55M (-592.8%)
|
-72.80M
-83.57M – -64.92M
-41.2% YoY
|
-103.63M
-118.44M – -92.29M
-42.3% YoY
|
-145.37M
-146.49M – -144.25M
-40.3% YoY
|
-178.26M
-210.61M – -157.98M
-22.6% YoY
|
-209.92M
-248.02M – -186.03M
-17.8% YoY
|
| EBIT |
-261.94M
est: -266.60M (+1.8%)
|
-398.88M
est: 47.6K (-838,096.6%)
|
-460.56M
est: -6.55M (-6,926.7%)
|
-395.28M
est: -32.49M (-1,116.4%)
|
-393.05M
est: -51.55M (-662.5%)
|
-72.80M
-83.57M – -64.92M
-41.2% YoY
|
-103.63M
-118.44M – -92.29M
-42.3% YoY
|
-145.37M
-146.49M – -144.25M
-40.3% YoY
|
-178.26M
-210.61M – -157.98M
-22.6% YoY
|
-209.92M
-248.02M – -186.03M
-17.8% YoY
|
| Net Income |
-259.58M
est: -264.23M (+1.8%)
|
-395.89M
est: -750.70M (+47.3%)
|
-444.04M
est: -623.67M (+28.8%)
|
-372.18M
est: -389.92M (+4.6%)
|
-390.98M
est: -382.37M (-2.3%)
|
-214.07M
-243.64M – -139.23M
+44.0% YoY
|
-121.06M
-133.98M – -79.92M
+43.5% YoY
|
436.6K
-194.1K – 1.07M
+100.4% YoY
|
42.88M
36.54M – 53.00M
+9,720.6% YoY
|
80.40M
68.51M – 99.37M
+87.5% YoY
|
| SGA |
60.21M
est: 647.38M (-90.7%)
|
104.10M
est: 4.47M (+2,230.1%)
|
106.92M
est: 612.39M (-82.5%)
|
153.02M
est: 3.04B (-95.0%)
|
152.32M
est: 4.82B (-96.8%)
|
6.80B
6.07B – 7.81B
+41.2% YoY
|
9.68B
8.62B – 11.07B
+42.3% YoY
|
13.58B
13.48B – 13.69B
+40.3% YoY
|
16.66B
14.76B – 19.68B
+22.6% YoY
|
19.61B
17.38B – 23.17B
+17.8% YoY
|
| EPS |
-1.88
est: -1.85 (-1.9%)
|
-2.49
est: -2.48 (-0.2%)
|
-1.89
est: -1.67 (-13.1%)
|
-1.28
est: -1.29 (+1.1%)
|
-1.09
est: -1.08 (-1.0%)
|
-0.54
-0.68 – -0.39
+50.0% YoY
|
-0.28
-0.37 – -0.22
+47.6% YoY
|
0.00
0.00 – 0.00
+100.4% YoY
|
0.12
0.10 – 0.15
+11,948.2% YoY
|
0.23
0.19 – 0.28
+87.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-135.09M
OE per share TTM
-0.35
Owner's Yield
-9.09%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
233.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
78
Total invested
38.49M
Insider transactions (90d)
0
Beneficial owners (>5%)
37
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Joseph Edelman | 19.22M | 6.90% | — | 19.22M | — | 19.22M | IN | Delaware | 2024-03-01 | ↗ |
| 2 | Perceptive Advisors LLC | 19.22M | 6.90% | — | 19.22M | — | 19.22M | IA | Delaware | 2024-03-01 | ↗ |
| 3 | Perceptive Life Sciences Master Fund, Ltd. | 19.22M | 6.90% | — | 19.22M | — | 19.22M | CO | Delaware | 2024-03-01 | ↗ |
| 4 | ARK Investment Management LLC | 15.30M | 10.43% | 14.52M | 466.1K | 15.30M | — | IA | Delaware, United States | 2021-01-11 | ↗ |
| 5 | STATE STREET CORPORATION | 14.72M | 9.32% | — | 14.28M | — | 14.72M | HC | BOSTON, MASSACHUSETTS | 2023-02-02 | ↗ |
| 6 | The Vanguard Group - 23-1945930 | 12.20M | 7.77% | — | 67.4K | 12.01M | 184.3K | IA | Pennsylvania | 2022-02-10 | ↗ |
| 7 | Mark H. Rachesky, M.D. | 12.08M | 6.70% | 12.08M | — | 12.08M | — | IN | Anguilla, British West Indies | 2022-12-30 | ↗ |
| 8 | (1) BlackRock, Inc. | 12.08M | 7.70% | 11.75M | — | 12.08M | — | HC | Delaware | 2023-02-03 | ↗ |
| 9 | MHR ADVISORS LLC | 12.00M | 6.70% | 12.00M | — | 12.00M | — | OO | Anguilla, British West Indies | 2022-12-30 | ↗ |
| 10 | MHR FUND MANAGEMENT LLC | 12.00M | 6.70% | 12.00M | — | 12.00M | — | OO | Anguilla, British West Indies | 2022-12-30 | ↗ |
| 11 | MHR HOLDINGS LLC | 12.00M | 6.70% | 12.00M | — | 12.00M | — | OO | Anguilla, British West Indies | 2022-12-30 | ↗ |
| 12 | MHRC LLC | 12.00M | 6.70% | 12.00M | — | 12.00M | — | OO | Anguilla, British West Indies | 2022-12-30 | ↗ |
| 13 | SSGA FUNDS MANAGEMENT, INC. | 11.61M | 7.36% | — | 11.58M | — | 11.61M | IA | BOSTON, MASSACHUSETTS | 2023-02-02 | ↗ |
| 14 | MHR Capital Partners Master Account LP | 10.51M | 5.80% | 10.51M | — | — | 10.51M | PN | Anguilla, British West Indies | 2022-12-30 | ↗ |
| 15 | Advisors LLC | 10.13M | 6.50% | — | 10.13M | — | 10.13M | IA | Delaware | 2022-02-14 | ↗ |
| 16 | Edelman | 10.13M | 6.50% | — | 10.13M | — | 10.13M | IN | Delaware | 2022-02-14 | ↗ |
| 17 | Sciences Master Fund, Ltd. | 10.13M | 6.50% | — | 10.13M | — | 10.13M | CO | Delaware | 2022-02-14 | ↗ |
| 18 | Wellington Group Holdings LLP | 9.58M | 6.11% | — | 8.38M | — | — | HC | Delaware | 2022-02-04 | ↗ |
| 19 | Wellington Investment Advisors Holdings LLP | 9.58M | 6.11% | — | 8.38M | — | — | HC | Delaware | 2022-02-04 | ↗ |
| 20 | Wellington Management Group LLP | 9.58M | 6.11% | — | 8.38M | — | — | HC | Delaware | 2022-02-04 | ↗ |
| 21 | Wellington Management Company LLP | 9.37M | 5.97% | — | 8.34M | — | — | IA | Delaware | 2022-02-04 | ↗ |
| 22 | Life Sciences Master Fund, Ltd. | 9.17M | 6.30% | — | 9.17M | — | 9.17M | CO | Islands | 2021-02-16 | ↗ |
| 23 | Avoro Capital Advisors LLC | 8.68M | 5.50% | 8.68M | — | 8.68M | — | IA, OO | Delaware | 2022-02-11 | ↗ |
| 24 | Behzad Aghazadeh | 8.68M | 5.50% | 8.68M | — | 8.68M | — | IN | United States | 2022-02-11 | ↗ |
| 25 | Steven A. Cohen | 8.11M | 5.00% | — | 8.11M | — | — | IN | United States | 2023-02-17 | ↗ |
| 26 | Point72 Asset Management, L.P. | 7.35M | 4.60% | — | 7.35M | — | — | PN | Delaware | 2023-02-17 | ↗ |
| 27 | Point72 Capital Advisors, Inc. | 7.35M | 4.60% | — | 7.35M | — | — | CO | Delaware | 2023-02-17 | ↗ |
| 28 | Prudential Financial, Inc. | 7.18M | 6.20% | — | 12.24M | — | 12.24M | HC | Delaware | 2019-02-14 | ↗ |
| 29 | Broadfin Capital, LLC | 5.09M | 6.75% | — | 5.09M | — | 5.09M | IA, OO | Delaware | 2018-02-13 | ↗ |
| 30 | Broadfin Healthcare Master Fund, Ltd. | 5.09M | 6.75% | — | 5.09M | — | 5.09M | CO | Delaware | 2018-02-13 | ↗ |
| 31 | Kevin Kotler | 5.09M | 6.75% | — | 5.09M | — | 5.09M | HC, IN | Delaware | 2018-02-13 | ↗ |
| 32 | 52-0556948 | 4.66M | 2.90% | 849.5K | — | 4.66M | — | IA | Maryland | 2022-02-14 | ↗ |
| 33 | OrbiMed Capital LLC | 4.21M | 3.42% | — | 4.21M | — | — | IA | Delaware | 2019-02-13 | ↗ |
| 34 | ACUTA CAPITAL PARTNERS LLC 45-2817402 | 3.81M | 6.10% | — | — | — | — | IA | STATE OF DELAWARE | 2017-02-13 | ↗ |
| 35 | NAME OF REPORTING | 2.48M | 3.92% | — | 2.48M | — | 2.48M | IA | Delaware | 2017-02-13 | ↗ |
| 36 | OrbiMed Advisors LLC | 1.34M | 1.09% | — | 1.34M | — | — | IA | Delaware | 2019-02-13 | ↗ |
| 37 | Cubist Systematic Strategies, LLC | 767.3K | 0.50% | — | 767.3K | — | — | OO | Delaware | 2023-02-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
78
-195 vs prev Q
New positions
17
Closed positions
199
Increased
48
Reduced
17
Put/Call ratio
0.00
Calls held
2.0K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 29.52M +3.6M (+13.7%) | 80.58M +24.3M (+43.1%) | 8.11% +0.349 pp | 0.00% +0.000 pp | USD7.63 -64.2% | 6 qtrs — |
| 2 | MHR FUND MANAGEMENT LLC | 28.97M +— (+0.0%) | 79.08M +16.2M (+25.8%) | 7.96% -0.702 pp | 6.81% +0.649 pp | USD6.24 -56.3% | 13 qtrs — |
| 3 | VANGUARD GROUP INC | 27.21M +3.1M (+13.1%) | 74.28M +22.1M (+42.3%) | 7.47% +0.281 pp | 0.00% +0.000 pp | USD11.00 -75.2% | 35 qtrs — |
| 4 | STATE STREET CORP | 20.16M +6.9M (+51.5%) | 55.04M +26.2M (+90.6%) | 5.54% +1.559 pp | 0.00% +0.001 pp | USD6.26 -56.4% | 35 qtrs — |
| 5 | BANK OF AMERICA CORP /DE/ | 14.28M +8.0M (+127.4%) | 38.98M +25.4M (+186.1%) | 3.92% +2.045 pp | 0.00% +0.002 pp | USD3.05 -10.5% | 35 qtrs — |
| 6 | INVENOMIC CAPITAL MANAGEMENT LP | 11.96M +1.4M (+13.5%) | 32.65M +9.8M (+42.7%) | 3.29% +0.134 pp | 1.52% +0.412 pp | USD2.66 +2.6% | 4 qtrs — |
| 7 | MORGAN STANLEY | 9.19M +3.6M (+64.7%) | 25.09M +13.0M (+107.2%) | 2.53% +0.856 pp | 0.00% +0.001 pp | USD4.31 -36.7% | 35 qtrs — |
| 8 | GOLDMAN SACHS GROUP INC | 8.61M +2.0M (+30.9%) | 23.50M +9.2M (+64.7%) | 2.36% +0.399 pp | 0.00% +0.001 pp | USD5.88 -53.6% | 35 qtrs — |
| 9 | LONG FOCUS CAPITAL MANAGEMENT, LLC | 8.60M -516.5K (-5.7%) | 23.48M +3.7M (+18.7%) | 2.36% -0.363 pp | 0.62% -0.036 pp | USD5.12 -46.7% | 17 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 7.99M +1.1M (+16.4%) | 21.82M +6.9M (+46.4%) | 2.20% +0.142 pp | 0.00% +0.000 pp | USD8.56 -68.1% | 35 qtrs — |
| 11 | PALO ALTO INVESTORS LP | 7.12M -501.5K (-6.6%) | 19.43M +2.9M (+17.5%) | 1.95% -0.323 pp | 2.70% -0.355 pp | USD4.72 -42.2% | 9 qtrs — |
| 12 | MILLENNIUM MANAGEMENT LLC | 6.59M +2.2M (+49.2%) | 17.98M +8.4M (+87.7%) | 1.81% +0.490 pp | 0.01% +0.004 pp | USD2.11 +29.4% | 17 qtrs — |
| 13 | TWO SIGMA INVESTMENTS, LP | 4.40M +1.7M (+60.5%) | 12.01M +6.1M (+101.9%) | 1.21% +0.389 pp | 0.02% +0.008 pp | USD2.19 +24.7% | 7 qtrs — |
| 14 | HRT FINANCIAL LP | 4.36M +4.0M (+1,078.3%) | 11.89M +11.1M (+1,382.7%) | 1.20% +1.086 pp | 0.04% +0.035 pp | USD2.70 +1.1% | 4 qtrs — |
| 15 | D. E. SHAW & CO., INC. | 3.83M +3.8M (+4,925.4%) | 10.46M +10.3M (+6,222.2%) | 1.05% +1.029 pp | 0.01% +0.006 pp | USD2.81 -2.8% | 25 qtrs — |
| 16 | TWO SIGMA ADVISERS, LP | 3.02M +2.0M (+184.7%) | 8.23M +5.9M (+258.2%) | 0.83% +0.512 pp | 0.02% +0.011 pp | USD2.38 +14.7% | 3 qtrs — |
| 17 | JPMORGAN CHASE & CO | 3.00M +1.8M (+145.3%) | 8.19M +5.5M (+208.5%) | 0.82% +0.459 pp | 0.00% +0.000 pp | USD8.21 -66.7% | 35 qtrs — |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.75M +248.8K (+9.9%) | 7.52M +2.1M (+38.3%) | 0.76% +0.008 pp | 0.00% +0.000 pp | USD7.93 -65.6% | 35 qtrs — |
| 19 | NORTHERN TRUST CORP | 2.58M +118.5K (+4.8%) | 7.04M +1.7M (+31.9%) | 0.71% -0.027 pp | 0.00% +0.000 pp | USD7.93 -65.6% | 35 qtrs — |
| 20 | WELLS FARGO & COMPANY/MN | 1.99M +476.0K (+31.4%) | 5.44M +2.1M (+65.3%) | 0.55% +0.094 pp | 0.00% +0.000 pp | USD3.95 -30.9% | 35 qtrs — |
| 21 | ORION INVESTMENT CO | 1.86M +5.2K (+0.3%) | 5.07M +1.1M (+26.2%) | 0.51% -0.044 pp | 1.54% +0.268 pp | USD4.69 -41.8% | 7 qtrs — |
| 22 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 1.60M +497.5K (+45.3%) | 4.36M +2.0M (+82.8%) | 0.44% +0.110 pp | 0.41% +0.143 pp | USD5.13 -46.8% | 35 qtrs — |
| 23 | DIMENSIONAL FUND ADVISORS LP | 1.54M -1.3M (-45.5%) | 4.20M -1.9M (-31.4%) | 0.42% -0.421 pp | 0.00% 0.000 pp | USD7.61 -64.1% | 30 qtrs — |
| 24 | B GROUP, INC. | 1.50M +— (+0.0%) | 4.10M +840.0K (+25.8%) | 0.41% -0.036 pp | 3.02% +0.629 pp | USD6.02 -54.7% | 5 qtrs — |
| 25 | RICE HALL JAMES & ASSOCIATES, LLC | 1.43M -26.3K (-1.8%) | 3.89M +741.0K (+23.5%) | 0.39% -0.042 pp | 0.21% +0.042 pp | USD15.74 -82.7% | 24 qtrs — |
| 26 | NUVEEN, LLC | 1.39M +134.5K (+10.7%) | 3.78M +1.1M (+39.3%) | 0.38% +0.007 pp | 0.00% +0.000 pp | USD2.88 -5.2% | 4 qtrs — |
| 27 | C WORLDWIDE GROUP HOLDING A/S | 1.26M +— (+0.0%) | 3.44M +706.0K (+25.8%) | 0.35% -0.031 pp | 0.06% +0.018 pp | USD9.99 -72.7% | 15 qtrs — |
| 28 | INVESCO LTD. | 1.25M +306.2K (+32.4%) | 3.42M +1.4M (+66.5%) | 0.34% +0.061 pp | 0.00% +0.000 pp | USD3.67 -25.6% | 27 qtrs — |
| 29 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.19M -866.2K (-42.1%) | 3.26M -1.2M (-27.1%) | 0.33% -0.288 pp | 0.00% 0.000 pp | USD17.79 -84.7% | 32 qtrs — |
| 30 | BARCLAYS PLC | 1.13M +522.6K (+86.4%) | 3.08M -2.6M (-45.8%) | 0.31% +0.129 pp | 0.00% -0.001 pp | USD4.53 -39.7% | 34 qtrs — |
| 31 | MIRADOR CAPITAL PARTNERS LP | 1.03M +519.5K (+100.9%) | 2.82M +1.7M (+152.7%) | 0.28% +0.130 pp | 0.39% +0.229 pp | USD2.45 +11.4% | 2 qtrs — |
| 32 | BANK OF NEW YORK MELLON CORP | 955.5K +148.3K (+18.4%) | 2.61M +856.8K (+48.9%) | 0.26% +0.021 pp | 0.00% +0.000 pp | USD14.40 -81.0% | 35 qtrs — |
| 33 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 914.4K +2.4K (+0.3%) | 2.50M +517.2K (+26.1%) | 0.25% -0.022 pp | 0.04% +0.007 pp | USD2.17 +25.8% | 2 qtrs — |
| 34 | GSA CAPITAL PARTNERS LLP | 873.0K +793.8K (+1,001.9%) | 2.38M +2.2M (+1,285.5%) | 0.24% +0.216 pp | 0.21% +0.191 pp | USD2.66 +2.6% | 8 qtrs — |
| 35 | WALLEYE CAPITAL LLC | 822.8K +786.1K (+2,143.2%) | 2.25M +2.2M (+2,722.1%) | 0.23% +0.215 pp | 0.01% +0.007 pp | USD2.71 +0.7% | 2 qtrs — |
| 36 | UBS GROUP AG | 764.2K -172.4K (-18.4%) | 2.09M +53.9K (+2.7%) | 0.21% -0.070 pp | 0.00% +0.000 pp | USD7.57 -63.9% | 35 qtrs — |
| 37 | ABRDN PLC | 759.5K +152.3K (+25.1%) | 2.07M +755.8K (+57.4%) | 0.21% +0.027 pp | 0.00% +0.001 pp | USD3.08 -11.4% | 7 qtrs — |
| 38 | RAFFERTY ASSET MANAGEMENT, LLC | 706.5K +223.5K (+46.3%) | 1.93M +880.6K (+84.0%) | 0.19% +0.050 pp | 0.01% +0.003 pp | USD5.46 -50.0% | 28 qtrs — |
| 39 | DEUTSCHE BANK AG\ | 690.4K +45.0K (+7.0%) | 1.88M +484.2K (+34.6%) | 0.19% -0.003 pp | 0.00% +0.000 pp | USD7.57 -63.9% | 35 qtrs — |
| 40 | QVT FINANCIAL LP | 678.6K +— (+0.0%) | 1.85M +380.0K (+25.8%) | 0.19% -0.017 pp | 0.16% +0.055 pp | USD13.81 -80.2% | 35 qtrs — |
| 41 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 659.4K -260.8K (-28.3%) | 1.80M -196.7K (-9.8%) | 0.18% -0.094 pp | 0.00% +0.000 pp | USD4.73 -42.3% | 34 qtrs — |
| 42 | CITADEL ADVISORS LLC | 658.2K +11.0K (+1.7%) | 1.80M +392.5K (+27.9%) | 0.18% -0.013 pp | 0.00% +0.000 pp | USD7.52 -63.7% | 34 qtrs — |
| 43 | RENAISSANCE TECHNOLOGIES LLC | 651.0K +651.0K (+100.0%) | 1.78M +1.8M (+100.0%) | 0.18% +0.179 pp | 0.00% +0.003 pp | USD2.73 +0.0% | 4 qtrs — |
| 44 | VOLEON CAPITAL MANAGEMENT LP | 630.3K +490.3K (+350.3%) | 1.72M +1.4M (+466.5%) | 0.17% +0.131 pp | 0.04% +0.030 pp | USD2.51 +8.8% | 3 qtrs — |
| 45 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 628.5K +497.5K (+379.8%) | 1.72M +1.4M (+503.6%) | 0.17% +0.134 pp | 0.00% +0.002 pp | USD2.61 +4.6% | 2 qtrs — |
| 46 | LPL FINANCIAL LLC | 623.1K +11.7K (+1.9%) | 1.70M +374.3K (+28.2%) | 0.17% -0.012 pp | 0.00% +0.000 pp | USD6.20 -56.0% | 22 qtrs — |
| 47 | ROYAL BANK OF CANADA | 608.5K -946.4K (-60.9%) | 1.66M -1.7M (-50.8%) | 0.17% -0.298 pp | 0.00% 0.000 pp | USD2.53 +7.9% | 35 qtrs — |
| 48 | SWISS NATIONAL BANK | 606.5K +88.4K (+17.1%) | 1.66M +531.4K (+47.3%) | 0.17% +0.012 pp | 0.00% +0.000 pp | USD7.72 -64.6% | 35 qtrs — |
| 49 | WOODLINE PARTNERS LP | 567.7K +— (+0.0%) | 1.55M +317.9K (+25.8%) | 0.16% -0.014 pp | 0.01% +0.000 pp | USD9.34 -70.8% | 10 qtrs — |
| 50 | QUBE RESEARCH & TECHNOLOGIES LTD | 564.5K +564.5K (+100.0%) | 1.54M +1.5M (+100.0%) | 0.16% +0.155 pp | 0.00% +0.002 pp | USD2.73 +0.0% | 1 qtrs NEW |
| 51 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 525.5K +253.6K (+93.2%) | 1.43M +844.5K (+143.1%) | 0.14% +0.063 pp | 0.02% +0.013 pp | USD2.54 +7.5% | 15 qtrs — |
| 52 | XTX TOPCO LTD | 522.9K +312.4K (+148.4%) | 1.43M +970.8K (+212.5%) | 0.14% +0.081 pp | 0.04% +0.014 pp | USD2.59 +5.4% | 4 qtrs — |
| 53 | UBS ASSET MANAGEMENT AMERICAS INC | 469.7K -12.1K (-2.5%) | 1.28M +236.8K (+22.7%) | 0.13% -0.015 pp | 0.00% +0.000 pp | USD5.22 -47.7% | 35 qtrs — |
| 54 | RHUMBLINE ADVISERS | 461.3K +67.2K (+17.1%) | 1.26M +404.2K (+47.3%) | 0.13% +0.009 pp | 0.00% +0.000 pp | USD8.57 -68.1% | 35 qtrs — |
| 55 | CRESSET ASSET MANAGEMENT, LLC | 457.8K +267.3K (+140.3%) | 1.25M +836.4K (+202.3%) | 0.13% +0.069 pp | 0.01% +0.004 pp | USD3.88 -29.6% | 20 qtrs — |
| 56 | RAIFFEISEN BANK INTERNATIONAL AG | 450.0K +210.0K (+87.5%) | 1.25M +711.3K (+132.9%) | 0.12% +0.052 pp | 0.02% +0.009 pp | USD3.73 -26.8% | 5 qtrs — |
| 57 | ALGERT GLOBAL LLC | 434.0K +434.0K (+100.0%) | 1.19M +1.2M (+100.0%) | 0.12% +0.119 pp | 0.02% +0.019 pp | USD2.73 +0.0% | 1 qtrs NEW |
| 58 | HENNION & WALSH ASSET MANAGEMENT, INC. | 410.2K -134.1K (-24.6%) | 1.12M -61.4K (-5.2%) | 0.11% -0.050 pp | 0.04% -0.004 pp | USD7.59 -64.0% | 17 qtrs — |
| 59 | RAYMOND JAMES FINANCIAL INC | 404.4K +68.3K (+20.3%) | 1.10M +374.7K (+51.4%) | 0.11% +0.011 pp | 0.00% +0.000 pp | USD6.39 -57.3% | 5 qtrs — |
| 60 | CM MANAGEMENT, LLC | 400.0K -300.0K (-42.9%) | 1.09M -427.0K (-28.1%) | 0.11% -0.099 pp | 0.92% -0.346 pp | USD3.85 -29.1% | 10 qtrs — |
| 61 | STIFEL FINANCIAL CORP | 329.8K -19.8K (-5.7%) | 900.4K +141.8K (+18.7%) | 0.09% -0.014 pp | 0.00% +0.000 pp | USD4.70 -41.9% | 13 qtrs — |
| 62 | SIMPLEX TRADING, LLC | 329.1K +46.9K (+16.6%) | 898.3K +286.3K (+46.8%) | 0.09% +0.006 pp | 0.00% +0.000 pp | USD2.72 +0.4% | 17 qtrs — |
| 63 | QUADRATURE CAPITAL LTD | 318.7K +318.7K (+100.0%) | 870.1K +870.1K (+100.0%) | 0.09% +0.088 pp | 0.01% +0.009 pp | USD2.73 +0.0% | 4 qtrs — |
| 64 | KENNONDALE CAPITAL MANAGEMENT LLC | 318.2K +— (+0.0%) | 868.7K +178.2K (+25.8%) | 0.09% -0.008 pp | 0.64% +0.110 pp | USD1.85 +47.6% | 5 qtrs — |
| 65 | JAIN GLOBAL LLC | 312.1K +312.1K (+100.0%) | 852.0K +852.0K (+100.0%) | 0.09% +0.086 pp | 0.00% +0.004 pp | USD2.73 +0.0% | 4 qtrs — |
| 66 | VIRTUS INVESTMENT ADVISERS, INC. | 310.6K +118.3K (+61.5%) | 848.1K +430.6K (+103.1%) | 0.09% +0.028 pp | 0.23% +0.111 pp | USD2.34 +16.7% | 4 qtrs — |
| 67 | CORSAIR CAPITAL MANAGEMENT, L.P. | 300.0K +300.0K (+100.0%) | 819.0K +819.0K (+100.0%) | 0.08% +0.082 pp | 0.13% +0.127 pp | USD2.73 +0.0% | 1 qtrs NEW |
| 68 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 296.0K +45.1K (+18.0%) | 808.1K +263.5K (+48.4%) | 0.08% +0.006 pp | 0.00% +0.000 pp | USD8.47 -67.8% | 35 qtrs — |
| 69 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 281.5K +239.4K (+568.2%) | 768.4K +677.0K (+740.7%) | 0.08% +0.065 pp | 0.01% +0.005 pp | USD2.65 +3.0% | 4 qtrs — |
| 70 | PROFUND ADVISORS LLC | 260.7K +156.3K (+149.7%) | 711.6K +485.0K (+214.1%) | 0.07% +0.040 pp | 0.02% +0.014 pp | USD3.53 -22.7% | 12 qtrs — |
| 71 | ALLIANCEBERNSTEIN L.P. | 258.9K +— (+0.0%) | 706.8K +145.0K (+25.8%) | 0.07% -0.006 pp | 0.00% +0.000 pp | USD8.98 -69.6% | 35 qtrs — |
| 72 | LEGAL & GENERAL GROUP PLC | 258.7K +4.1K (+1.6%) | 706.2K +153.8K (+27.8%) | 0.07% -0.005 pp | 0.00% +0.000 pp | USD11.98 -77.2% | 35 qtrs — |
| 73 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 231.4K +6.2K (+2.8%) | 637.3K +148.6K (+30.4%) | 0.06% -0.004 pp | 0.00% +0.000 pp | USD11.66 -76.6% | 16 qtrs — |
| 74 | SCIENTECH RESEARCH LLC | 211.5K +211.5K (+100.0%) | 577.3K +577.3K (+100.0%) | 0.06% +0.058 pp | 0.36% +0.363 pp | USD2.73 +0.0% | 1 qtrs NEW |
| 75 | RUSSELL INVESTMENTS GROUP, LTD. | 198.0K +131.1K (+195.7%) | 540.7K +395.3K (+272.0%) | 0.05% +0.034 pp | 0.00% +0.000 pp | USD2.68 +1.9% | 16 qtrs — |
| 76 | PARAMETRICA MANAGEMENT LTD | 195.9K +— (+0.0%) | 534.7K +109.7K (+25.8%) | 0.05% -0.005 pp | 0.82% +0.166 pp | USD9.29 -70.6% | 19 qtrs — |
| 77 | — | 195.0K +100.0K (+105.3%) | 532.4K +326.2K (+158.2%) | 0.05% +0.025 pp | 0.02% +0.010 pp | USD2.24 +21.9% | 12 qtrs — |
| 78 | ENGINEERS GATE MANAGER LP | 194.7K +194.7K (+100.0%) | 531.5K +531.5K (+100.0%) | 0.05% +0.054 pp | 0.01% +0.006 pp | USD2.73 +0.0% | 1 qtrs NEW |
| 79 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 184.0K +39.1K (+26.9%) | 503.9K +187.9K (+59.5%) | 0.05% +0.007 pp | 0.00% +0.000 pp | USD6.90 -60.4% | 7 qtrs — |
| 80 | HSBC HOLDINGS PLC | 180.5K +156.5K (+651.5%) | 497.4K +445.1K (+851.9%) | 0.05% +0.042 pp | 0.00% +0.000 pp | USD2.94 -7.1% | 8 qtrs — |
| 81 | CAPITAL FUND MANAGEMENT S.A. | 181.1K -120.0K (-39.9%) | 494.3K -159.0K (-24.3%) | 0.05% -0.040 pp | 0.00% 0.000 pp | USD4.86 -43.8% | 7 qtrs — |
| 82 | TUDOR INVESTMENT CORP ET AL | 179.5K +57.8K (+47.4%) | 490.0K +225.8K (+85.5%) | 0.05% +0.013 pp | 0.00% +0.001 pp | USD2.35 +16.2% | 20 qtrs — |
| 83 | METLIFE INVESTMENT MANAGEMENT, LLC | 170.8K +29.1K (+20.5%) | 466.2K +158.8K (+51.6%) | 0.05% +0.005 pp | 0.00% +0.001 pp | USD8.04 -66.0% | 18 qtrs — |
| 84 | GROUP ONE TRADING, L.P. | 168.7K -261.2K (-60.8%) | 460.5K -472.3K (-50.6%) | 0.05% -0.082 pp | 0.00% -0.001 pp | USD6.68 -59.1% | 22 qtrs — |
| 85 | CREATIVE PLANNING | 158.7K +59.4K (+59.9%) | 433.1K +217.8K (+101.1%) | 0.04% +0.014 pp | 0.00% +0.000 pp | USD5.72 -52.3% | 10 qtrs — |
| 86 | BAIRD FINANCIAL GROUP, INC. | 157.5K -4.0K (-2.5%) | 430.1K +79.5K (+22.7%) | 0.04% -0.005 pp | 0.00% +0.000 pp | USD8.45 -67.7% | 9 qtrs — |
| 87 | PERCEPTIVE ADVISORS LLC | 152.7K +152.7K (+100.0%) | 416.9K +416.9K (+100.0%) | 0.04% +0.042 pp | 0.01% +0.007 pp | USD2.73 +0.0% | 1 qtrs NEW |
| 88 | QUANTITATIVE INVESTMENT MANAGEMENT, LLC | 138.6K +138.6K (+100.0%) | 378.0K +378.0K (+100.0%) | 0.04% +0.038 pp | 0.04% +0.037 pp | USD2.73 +0.0% | 1 qtrs NEW |
| 89 | INTECH INVESTMENT MANAGEMENT LLC | 136.8K +10.9K (+8.7%) | 373.4K +100.3K (+36.8%) | 0.04% +0.000 pp | 0.00% +0.001 pp | USD6.81 -59.9% | 6 qtrs — |
| 90 | INTELLECTUS PARTNERS, LLC | 132.4K +1.4K (+1.1%) | 361.6K +77.2K (+27.1%) | 0.04% -0.003 pp | 0.07% +0.015 pp | USD12.39 -78.0% | 25 qtrs — |
| 91 | JANE STREET GROUP, LLC | 130.6K +28.3K (+27.7%) | 356.5K +134.5K (+60.6%) | 0.04% +0.005 pp | 0.00% +0.000 pp | USD5.81 -53.0% | 6 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 108 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Genomics Immunology and Healthcare ETF IDNA | 1.80% | 3.53M | 0.47% |
| 2 | Virtus Biotech ETF BBP | 1.34% | 1.31M | 0.34% |
| 3 | WisdomTree BioRevolution UCITS ETF - USD Acc WDNA.L | 0.78% | 174.3K | 0.45% |
| 4 | Tema Oncology ETF CANC | 0.62% | 875.9K | 0.75% |
| 5 | Global X - S&P Biotech ETF CURE.AX | 0.57% | 204.7K | 0.45% |
| 6 | State Street SPDR S&P Biotech ETF XBI | 0.57% | 61.47M | 0.35% |
| 7 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.51% | 113.2K | 0.20% |
| 8 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.18% | 2.03M | 0.40% |
| 9 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.15% | 4.32M | 0.34% |
| 10 | iShares Ageing Population UCITS ETF AGED.L | 0.14% | 1.20M | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.70
Neutral
Ratio by volume
1.98
Bullish
Buys
16
Sells
23
Shares acquired
1.20M
Shares disposed
605.1K
Cash buys
—
Cash sales
—
Net activity
+594,640
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-09 | Vogt Frederick G | Director / Officer | A-Award | A | Restricted Stock Units | 235,000 | 0.00 | — | 235,000 | D | ↗ |
| 2026-03-09 | Roche Corleen M. | Officer | A-Award | A | Restricted Stock Units | 132,200 | 0.00 | — | 132,200 | D | ↗ |
| 2026-03-09 | Puri Raj K. | Officer | A-Award | A | Restricted Stock Units | 117,500 | 0.00 | — | 117,500 | D | ↗ |
| 2026-03-09 | Kirby Daniel Gordon | Officer | A-Award | A | Restricted Stock Units | 132,200 | 0.00 | — | 132,200 | D | ↗ |
| 2026-03-09 | GRAF FINCKENSTEIN FRIEDRICH | Officer | A-Award | A | Restricted Stock Units | 58,750 | 0.00 | — | 58,750 | D | ↗ |
| 2026-03-09 | BILINSKY IGOR | Officer | A-Award | A | Restricted Stock Units | 117,500 | 0.00 | — | 117,500 | D | ↗ |
| 2026-03-05 | Vogt Frederick G | Director / Officer | M-Exempt | D | Restricted Stock Units | 62,493 | 0.00 | — | 125,007 | D | ↗ |
| 2026-03-05 | Puri Raj K. | Officer | M-Exempt | D | Restricted Stock Units | 39,059 | 0.00 | — | 78,131 | D | ↗ |
| 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH | Officer | M-Exempt | D | Restricted Stock Units | 31,246 | 0.00 | — | 62,504 | D | ↗ |
| 2026-03-05 | BILINSKY IGOR | Officer | F-InKind | D | Common Stock | 16,628 | 4.58 | 76.2K | 125,766 | D | ↗ |
| 2026-03-02 | Vogt Frederick G | Director / Officer | M-Exempt | D | Restricted Stock Units | 10,418 | 0.00 | — | 0 | D | ↗ |
| 2026-03-02 | Puri Raj K. | Officer | M-Exempt | D | Restricted Stock Units | 5,470 | 0.00 | — | 21,878 | D | ↗ |
| 2026-03-02 | GRAF FINCKENSTEIN FRIEDRICH | Officer | M-Exempt | D | Restricted Stock Units | 3,907 | 0.00 | — | 0 | D | ↗ |
| 2026-03-02 | BILINSKY IGOR | Officer | M-Exempt | D | Restricted Stock Units | 3,517 | 0.00 | — | 0 | D | ↗ |
| 2026-02-24 | Kirby Daniel Gordon | Officer | M-Exempt | A | Common Stock | 120,000 | 0.00 | — | 173,546 | D | ↗ |
| 2026-02-10 | Kirby Daniel Gordon | Officer | F-InKind | D | Common Stock | 16,450 | 2.60 | 42.8K | 53,546 | D | ↗ |
| 2025-12-02 | Vogt Frederick G | Director / Officer | M-Exempt | D | Restricted Stock Units | 10,417 | 0.00 | — | 10,418 | D | ↗ |
| 2025-12-02 | GRAF FINCKENSTEIN FRIEDRICH | Officer | M-Exempt | A | Common Stock | 3,906 | 0.00 | — | 113,640 | D | ↗ |
| 2025-12-02 | BILINSKY IGOR | Officer | M-Exempt | A | Common Stock | 3,516 | 0.00 | — | 107,530 | D | ↗ |
| 2025-12-01 | Vogt Frederick G | Director / Officer | M-Exempt | D | Restricted Stock Units | 41,669 | 0.00 | — | 208,344 | D | ↗ |
| 2025-12-01 | Puri Raj K. | Officer | M-Exempt | D | Restricted Stock Units | 5,469 | 0.00 | — | 27,348 | D | ↗ |
| 2025-12-01 | GRAF FINCKENSTEIN FRIEDRICH | Officer | M-Exempt | D | Restricted Stock Units | 8,789 | 0.00 | — | 43,949 | D | ↗ |
| 2025-12-01 | BILINSKY IGOR | Officer | M-Exempt | D | Restricted Stock Units | 8,789 | 0.00 | — | 43,949 | D | ↗ |
| 2025-09-02 | Vogt Frederick G | Director / Officer | M-Exempt | D | Restricted Stock Units | 10,417 | 0.00 | — | 20,385 | D | ↗ |
| 2025-09-02 | Puri Raj K. | Officer | M-Exempt | D | Restricted Stock Units | 5,470 | 0.00 | — | 32,817 | D | ↗ |
| 2025-09-02 | GRAF FINCKENSTEIN FRIEDRICH | Officer | M-Exempt | A | Common Stock | 12,697 | 0.00 | — | 111,857 | D | ↗ |
| 2025-09-02 | BILINSKY IGOR | Officer | M-Exempt | D | Restricted Stock Units | 8,790 | 0.00 | — | 52,738 | D | ↗ |
| 2025-08-06 | Roche Corleen M. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-30 | Rosinack Matthew W. | Officer | — | — | Common Stock | 0 | 0.00 | — | 89,129 | D | ↗ |
| 2025-06-13 | YARNO WENDY L | Director | A-Award | A | Deferred Restricted Stock Unit | 67,546 | 0.00 | — | 67,546 | D | ↗ |
| 2025-06-13 | WEISER MICHAEL | Director | A-Award | A | Deferred Restricted Stock Unit | 67,546 | 0.00 | — | 67,546 | D | ↗ |
| 2025-06-13 | Maynard Ryan D | Director | A-Award | A | Deferred Restricted Stock Unit | 67,546 | 0.00 | — | 67,546 | D | ↗ |
| 2025-06-13 | Dukes Iain D. | Director | A-Award | A | Deferred Restricted Stock Unit | 135,092 | 0.00 | — | 135,092 | D | ↗ |
| 2025-06-13 | Countouriotis Athena | Director | A-Award | A | Deferred Restricted Stock Unit | 67,546 | 0.00 | — | 67,546 | D | ↗ |
| 2025-06-05 | Kirby Daniel Gordon | Officer | P-Purchase | A | Common Stock | 30,000 | 1.84 | 55.2K | 30,000 | D | ↗ |
| 2025-06-02 | Vogt Frederick G | Director / Officer | M-Exempt | D | Restricted Stock Units | 10,417 | 0.00 | — | 31,252 | D | ↗ |
| 2025-06-02 | Puri Raj K. | Officer | M-Exempt | D | Restricted Stock Units | 5,469 | 0.00 | — | 38,287 | D | ↗ |
| 2025-06-02 | GRAF FINCKENSTEIN FRIEDRICH | Officer | M-Exempt | D | Restricted Stock Units | 8,789 | 0.00 | — | 61,528 | D | ↗ |
| 2025-06-02 | Bellemin Jean-Marc | Officer | F-InKind | D | Common Stock | 4,464 | 1.76 | 7.9K | 60,529 | D | ↗ |
| 2025-06-02 | BILINSKY IGOR | Officer | M-Exempt | D | Restricted Stock Units | 3,516 | 0.00 | — | 10,549 | D | ↗ |
| 2025-05-23 | Puri Raj K. | Officer | P-Purchase | A | Common Stock | 5,600 | 1.74 | 9.7K | 206,852 | D | ↗ |
| 2025-05-14 | Vogt Frederick G | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 1.69 | 42.3K | 374,646 | D | ↗ |
| 2025-03-14 | Puri Raj K. | Officer | M-Exempt | A | Common Stock | 8,334 | 0.00 | — | 203,761 | D | ↗ |
| 2025-03-05 | Vogt Frederick G | Director / Officer | A-Award | A | Restricted Stock Units | 187,500 | 0.00 | — | 187,500 | D | ↗ |
| 2025-03-05 | Puri Raj K. | Officer | A-Award | A | Restricted Stock Units | 117,190 | 0.00 | — | 117,190 | D | ↗ |
| 2025-03-05 | GRAF FINCKENSTEIN FRIEDRICH | Officer | A-Award | A | Restricted Stock Units | 93,750 | 0.00 | — | 93,750 | D | ↗ |
| 2025-03-05 | Bellemin Jean-Marc | Officer | A-Award | A | Restricted Stock Units | 93,750 | 0.00 | — | 93,750 | D | ↗ |
| 2025-03-05 | BILINSKY IGOR | Officer | A-Award | A | Restricted Stock Units | 93,750 | 0.00 | — | 93,750 | D | ↗ |
| 2025-03-03 | Vogt Frederick G | Director / Officer | F-InKind | D | Common Stock | 95,413 | 4.04 | 385.5K | 349,646 | D | ↗ |
| 2025-03-03 | Puri Raj K. | Officer | M-Exempt | D | Restricted Stock Units | 59,999 | 0.00 | — | 43,756 | D | ↗ |
| 2025-03-03 | GRAF FINCKENSTEIN FRIEDRICH | Officer | M-Exempt | D | Restricted Stock Units | 3,907 | 0.00 | — | 15,626 | D | ↗ |
| 2025-03-03 | Bellemin Jean-Marc | Officer | F-InKind | D | Common Stock | 31,734 | 4.04 | 128.2K | 56,204 | D | ↗ |
| 2025-03-03 | BILINSKY IGOR | Officer | M-Exempt | D | Restricted Stock Units | 3,516 | 0.00 | — | 14,065 | D | ↗ |
| 2025-02-10 | Kirby Daniel Gordon | Officer | A-Award | A | Performance Stock Units | 150,000 | 0.00 | — | 150,000 | D | ↗ |
| 2025-01-14 | Vogt Frederick G | Director / Officer | M-Exempt | A | Common Stock | 20,835 | 0.00 | — | 231,071 | D | ↗ |
| 2025-01-14 | GRAF FINCKENSTEIN FRIEDRICH | Officer | F-InKind | D | Common Stock | 1,578 | 5.89 | 9.3K | 63,886 | D | ↗ |
| 2025-01-14 | BILINSKY IGOR | Officer | M-Exempt | D | Restricted Stock Units | 2,813 | 0.00 | — | 0 | D | ↗ |
| 2024-12-16 | Puri Raj K. | Officer | M-Exempt | A | Common Stock | 8,334 | 0.00 | — | 159,171 | D | ↗ |
| 2024-12-02 | Vogt Frederick G | Director / Officer | M-Exempt | D | Restricted Stock Units | 10,417 | 0.00 | — | 52,087 | D | ↗ |
| 2024-12-02 | GRAF FINCKENSTEIN FRIEDRICH | Officer | F-InKind | D | Common Stock | 1,982 | 9.07 | 18.0K | 62,651 | D | ↗ |
| 2024-12-02 | BILINSKY IGOR | Officer | F-InKind | D | Common Stock | 1,784 | 9.07 | 16.2K | 57,539 | D | ↗ |
| 2024-11-22 | Puri Raj K. | Officer | — | — | Common Stock | 0 | 0.00 | — | 150,837 | D | ↗ |
| 2024-11-12 | Maynard Ryan D | Director | M-Exempt | A | Common Stock | 50,000 | 7.45 | 372.5K | 57,500 | D | ↗ |
| 2024-10-14 | Vogt Frederick G | Director / Officer | M-Exempt | D | Restricted Stock Units | 20,834 | 0.00 | — | 20,835 | D | ↗ |
| 2024-10-14 | GRAF FINCKENSTEIN FRIEDRICH | Officer | F-InKind | D | Common Stock | 1,428 | 9.77 | 14.0K | 60,727 | D | ↗ |
| 2024-10-14 | BILINSKY IGOR | Officer | M-Exempt | D | Restricted Stock Units | 2,813 | 0.00 | — | 2,813 | D | ↗ |
| 2024-09-03 | Vogt Frederick G | Director / Officer | M-Exempt | D | Restricted Stock Units | 10,417 | 0.00 | — | 62,504 | — | ↗ |
| 2024-09-03 | GRAF FINCKENSTEIN FRIEDRICH | Officer | M-Exempt | D | Restricted Stock Units | 3,907 | 0.00 | — | 23,439 | — | ↗ |
| 2024-09-03 | Bellemin Jean-Marc | Officer | M-Exempt | D | Restricted Stock Units | 23,438 | 0.00 | — | 23,437 | — | ↗ |
| 2024-09-03 | BILINSKY IGOR | Officer | M-Exempt | D | Restricted Stock Units | 3,516 | 0.00 | — | 21,097 | — | ↗ |
| 2024-07-15 | Vogt Frederick G | Officer | M-Exempt | A | Common Stock | 20,835 | 0.00 | — | 168,160 | — | ↗ |
| 2024-07-15 | GRAF FINCKENSTEIN FRIEDRICH | Officer | M-Exempt | A | Common Stock | 2,813 | 0.00 | — | 47,299 | — | ↗ |
| 2024-07-15 | BILINSKY IGOR | Officer | M-Exempt | A | Common Stock | 2,813 | 0.00 | — | 42,571 | — | ↗ |
| 2024-06-11 | YARNO WENDY L | Director | A-Award | A | Deferred Restricted Stock Unit | 49,303 | 0.00 | — | 49,303 | — | ↗ |
| 2024-06-11 | WEISER MICHAEL | Director | A-Award | A | Deferred Restricted Stock Unit | 49,303 | 0.00 | — | 49,303 | — | ↗ |
| 2024-06-11 | Maynard Ryan D | Director | A-Award | A | Deferred Restricted Stock Unit | 49,303 | 0.00 | — | 49,303 | — | ↗ |
| 2024-06-11 | Dukes Iain D. | Director | A-Award | A | Deferred Restricted Stock Unit | 98,607 | 0.00 | — | 98,607 | — | ↗ |
| 2024-06-11 | Countouriotis Athena | Director | A-Award | A | Deferred Restricted Stock Unit | 49,303 | 0.00 | — | 49,303 | — | ↗ |
| 2024-06-03 | Vogt Frederick G | Officer | M-Exempt | A | Common Stock | 10,417 | 0.00 | — | 151,751 | — | ↗ |
| 2024-06-03 | GRAF FINCKENSTEIN FRIEDRICH | Officer | M-Exempt | A | Common Stock | 3,906 | 0.00 | — | 46,468 | — | ↗ |
| 2024-06-03 | BILINSKY IGOR | Officer | M-Exempt | A | Common Stock | 3,516 | 0.00 | — | 41,542 | — | ↗ |
| 2024-04-15 | Vogt Frederick G | Officer | M-Exempt | A | Common Stock | 20,834 | 0.00 | — | 150,185 | — | ↗ |
| 2024-04-15 | GRAF FINCKENSTEIN FRIEDRICH | Officer | F-InKind | D | Common Stock | 1,427 | 11.89 | 17.0K | 42,562 | — | ↗ |
| 2024-04-15 | BILINSKY IGOR | Officer | M-Exempt | D | Restricted Stock Units | 2,812 | 0.00 | — | 8,439 | — | ↗ |
| 2024-03-04 | Vogt Frederick G | Officer | F-InKind | D | Common Stock | 11,449 | 16.96 | 194.2K | 129,351 | — | ↗ |
| 2024-03-04 | GRAF FINCKENSTEIN FRIEDRICH | Officer | F-InKind | D | Common Stock | 8,053 | 16.96 | 136.6K | 41,177 | — | ↗ |
| 2024-03-04 | BILINSKY IGOR | Officer | M-Exempt | D | Restricted Stock Units | 14,061 | 0.00 | — | 28,129 | — | ↗ |
| 2024-03-01 | YARNO WENDY L | Director | A-Award | A | Deferred Restricted Stock Unit | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2024-03-01 | WEISER MICHAEL | Director | A-Award | A | Deferred Restricted Stock Unit | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2024-03-01 | Vogt Frederick G | Officer | A-Award | A | Restricted Stock Units | 93,750 | 0.00 | — | 93,750 | — | ↗ |
| 2024-03-01 | Rothbaum Wayne P. | Director | A-Award | A | Deferred Restricted Stock Unit | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2024-03-01 | Maynard Ryan D | Director | A-Award | A | Deferred Restricted Stock Unit | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2024-03-01 | MCPEAK MERRILL A | Director | A-Award | A | Deferred Restricted Stock Unit | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2024-03-01 | GRAF FINCKENSTEIN FRIEDRICH | Officer | A-Award | A | Restricted Stock Units | 46,875 | 0.00 | — | 46,875 | — | ↗ |
| 2024-03-01 | Dukes Iain D. | Director | A-Award | A | Deferred Restricted Stock Unit | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2024-03-01 | Countouriotis Athena | Director | A-Award | A | Deferred Restricted Stock Unit | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2024-03-01 | Bellemin Jean-Marc | Officer | A-Award | A | Restricted Stock Units | 105,470 | 0.00 | — | 105,470 | — | ↗ |
| 2024-03-01 | BILINSKY IGOR | Officer | A-Award | A | Restricted Stock Units | 46,875 | 0.00 | — | 46,875 | — | ↗ |
| 2024-02-20 | Rothbaum Wayne P. | Director | P-Purchase | A | Common Stock | 5,000,000 | 9.15 | 45.75M | 28,067,333 | — | ↗ |
| 2024-02-20 | MCPEAK MERRILL A | Director | P-Purchase | A | Common Stock | 250,000 | 9.15 | 2.29M | 320,150 | — | ↗ |
| 2024-02-20 | Dukes Iain D. | Director | P-Purchase | A | Common Stock | 32,000 | 9.15 | 292.8K | 54,000 | — | ↗ |
| 2024-01-16 | Vogt Frederick G | Officer | M-Exempt | A | Common Stock | 20,834 | 0.00 | — | 105,668 | — | ↗ |
| 2024-01-16 | GRAF FINCKENSTEIN FRIEDRICH | Officer | F-InKind | D | Common Stock | 1,577 | 8.37 | 13.2K | 33,607 | — | ↗ |
| 2024-01-16 | BILINSKY IGOR | Officer | M-Exempt | D | Restricted Stock Units | 2,813 | 0.00 | — | 11,251 | — | ↗ |
| 2023-10-16 | Vogt Frederick G | Officer | M-Exempt | A | Common Stock | 20,835 | 0.00 | — | 93,685 | — | ↗ |
| 2023-10-16 | GRAF FINCKENSTEIN FRIEDRICH | Officer | M-Exempt | D | Restricted Stock Units | 2,813 | 0.00 | — | 14,064 | — | ↗ |
| 2023-10-16 | BILINSKY IGOR | Officer | M-Exempt | D | Restricted Stock Units | 2,813 | 0.00 | — | 14,064 | — | ↗ |
| 2023-09-18 | MCPEAK MERRILL A | Director | P-Purchase | A | Common Stock | 10,000 | 5.56 | 55.6K | 248,633 | — | ↗ |
| 2023-09-15 | Rothbaum Wayne P. | Director | P-Purchase | A | Common Stock | 5,000,000 | 5.30 | 26.50M | 23,067,333 | — | ↗ |
| 2023-07-14 | Vogt Frederick G | Officer | F-InKind | D | Common Stock | 8,851 | 7.76 | 68.7K | 72,850 | — | ↗ |
| 2023-07-14 | GRAF FINCKENSTEIN FRIEDRICH | Officer | F-InKind | D | Common Stock | 1,395 | 7.76 | 10.8K | 30,953 | — | ↗ |
| 2023-07-14 | BILINSKY IGOR | Officer | M-Exempt | D | Restricted Stock Units | 2,813 | 0.00 | — | 16,877 | — | ↗ |
| 2023-06-06 | YARNO WENDY L | Director | A-Award | A | Deferred Restricted Stock Unit | 12,988 | 0.00 | — | 12,988 | — | ↗ |
| 2023-06-06 | WEISER MICHAEL | Director | A-Award | A | Deferred Restricted Stock Unit | 51,955 | 0.00 | — | 51,955 | — | ↗ |
| 2023-06-06 | Maynard Ryan D | Director | A-Award | A | Deferred Restricted Stock Unit | 51,955 | 0.00 | — | 51,955 | — | ↗ |
| 2023-06-06 | MCPEAK MERRILL A | Director | A-Award | A | Deferred Restricted Stock Unit | 51,955 | 0.00 | — | 51,955 | — | ↗ |
| 2023-06-06 | Dukes Iain D. | Director | A-Award | A | Deferred Restricted Stock Unit | 103,911 | 0.00 | — | 103,911 | — | ↗ |
| 2023-06-06 | Countouriotis Athena | Director | A-Award | A | Deferred Restricted Stock Unit | 51,955 | 0.00 | — | 51,955 | — | ↗ |
| 2023-04-18 | YARNO WENDY L | Director | A-Award | A | Deferred Restricted Stock Unit | 74,823 | 0.00 | — | 74,823 | — | ↗ |
| 2023-04-14 | Vogt Frederick G | Officer | F-InKind | D | Common Stock | 8,851 | 5.64 | 49.9K | 60,867 | — | ↗ |
| 2023-04-14 | GRAF FINCKENSTEIN FRIEDRICH | Officer | F-InKind | D | Common Stock | 1,395 | 5.64 | 7.9K | 29,535 | — | ↗ |
| 2023-04-14 | BILINSKY IGOR | Officer | M-Exempt | D | Restricted Stock Units | 2,812 | 0.00 | — | 19,690 | — | ↗ |
| 2023-03-02 | Vogt Frederick G | Officer | A-Award | A | Stock Option (right to buy) | 500,000 | 7.12 | 3.56M | 500,000 | — | ↗ |
| 2023-03-02 | GRAF FINCKENSTEIN FRIEDRICH | Officer | A-Award | A | Restricted Stock Units | 46,875 | 0.00 | — | 46,875 | — | ↗ |
| 2023-03-02 | Bellemin Jean-Marc | Officer | A-Award | A | Stock Option (right to buy) | 168,750 | 7.12 | 1.20M | 168,750 | — | ↗ |
| 2023-03-02 | BILINSKY IGOR | Officer | A-Award | A | Stock Option (right to buy) | 84,380 | 7.12 | 600.8K | 84,380 | — | ↗ |
| 2023-01-17 | Vogt Frederick G | Officer | M-Exempt | D | Restricted Stock Units | 83,325 | 0.00 | — | 166,675 | — | ↗ |
| 2023-01-17 | GRAF FINCKENSTEIN FRIEDRICH | Officer | M-Exempt | A | Common Stock | 11,248 | 0.00 | — | 32,796 | — | ↗ |
| 2023-01-17 | BILINSKY IGOR | Officer | M-Exempt | A | Common Stock | 11,248 | 0.00 | — | 29,049 | — | ↗ |
| 2023-01-03 | GRAF FINCKENSTEIN FRIEDRICH | Officer | M-Exempt | D | Restricted Stock Units | 19,690 | 0.00 | — | 0 | — | ↗ |
| 2023-01-03 | Bellemin Jean-Marc | Officer | M-Exempt | D | Restricted Stock Units | 18,850 | 0.00 | — | 0 | — | ↗ |
| 2023-01-03 | BILINSKY IGOR | Officer | F-InKind | D | Common Stock | 10,553 | 6.11 | 64.5K | 17,801 | — | ↗ |
| 2022-12-21 | MCPEAK MERRILL A | Director | P-Purchase | A | Common Stock | 10,000 | 6.15 | 61.5K | 70,150 | — | ↗ |
| 2022-12-02 | Rothbaum Wayne P. | Director | P-Purchase | A | Common Stock | 10,000,000 | 6.50 | 65.00M | 18,067,333 | — | ↗ |
| 2022-11-29 | MCPEAK MERRILL A | Director | P-Purchase | A | Common Stock | 10,000 | 6.31 | 63.1K | 238,633 | — | ↗ |
| 2022-11-28 | Vogt Frederick G | Officer | P-Purchase | A | Common Stock | 1,000 | 5.98 | 6.0K | 2,000 | — | ↗ |
| 2022-11-28 | MCPEAK MERRILL A | Director | P-Purchase | A | Common Stock | 10,000 | 6.18 | 61.8K | 228,633 | — | ↗ |
| 2022-11-23 | Dukes Iain D. | Director | P-Purchase | A | Common Stock | 10,000 | 6.10 | 61.0K | 22,000 | — | ↗ |
| 2022-08-23 | MCPEAK MERRILL A | Director | M-Exempt | A | Common Stock | 40,000 | 5.65 | 226.0K | 60,150 | — | ↗ |
| 2022-06-14 | GRAF FINCKENSTEIN FRIEDRICH | Officer | A-Award | A | Restricted Stock Units | 19,690 | 0.00 | — | 19,690 | — | ↗ |
| 2022-06-14 | Bellemin Jean-Marc | Officer | M-Exempt | A | Common Stock | 18,850 | 0.00 | — | 18,850 | — | ↗ |
| 2022-06-14 | BILINSKY IGOR | Officer | M-Exempt | A | Common Stock | 18,850 | 0.00 | — | 18,850 | — | ↗ |
| 2022-06-10 | WEISER MICHAEL | Director | A-Award | A | Deferred Restricted Stock Unit | 51,204 | 0.00 | — | 51,204 | — | ↗ |
| 2022-06-10 | Maynard Ryan D | Director | A-Award | A | Deferred Restricted Stock Unit | 51,204 | 0.00 | — | 51,204 | — | ↗ |
| 2022-06-10 | MCPEAK MERRILL A | Director | A-Award | A | Deferred Restricted Stock Unit | 51,204 | 0.00 | — | 51,204 | — | ↗ |
| 2022-06-10 | Dukes Iain D. | Director | A-Award | A | Deferred Restricted Stock Unit | 102,409 | 0.00 | — | 102,409 | — | ↗ |
| 2022-06-10 | DIXON WENDY L | Director | A-Award | A | Deferred Restricted Stock Unit | 51,204 | 0.00 | — | 51,204 | — | ↗ |
| 2022-06-10 | Countouriotis Athena | Director | A-Award | A | Deferred Restricted Stock Unit | 51,204 | 0.00 | — | 51,204 | — | ↗ |
| 2022-06-01 | Vogt Frederick G | Officer | P-Purchase | A | Common Stock | 1,000 | 6.44 | 6.4K | 1,000 | — | ↗ |
| 2022-06-01 | Rothbaum Wayne P. | Director | P-Purchase | A | Common Stock | 500,000 | 6.43 | 3.22M | 8,067,333 | — | ↗ |
| 2022-05-31 | WEISER MICHAEL | Director | P-Purchase | A | Common Stock | 2,187 | 6.79 | 14.8K | 104,819 | — | ↗ |
| 2022-05-31 | Rothbaum Wayne P. | Director | P-Purchase | A | Common Stock | 500,000 | 6.77 | 3.38M | 7,567,333 | — | ↗ |
| 2022-05-31 | Maynard Ryan D | Director | P-Purchase | A | Common Stock | 7,500 | 6.75 | 50.6K | 7,500 | — | ↗ |
| 2022-05-31 | MCPEAK MERRILL A | Director | P-Purchase | A | Common Stock | 10,000 | 6.84 | 68.4K | 20,150 | — | ↗ |
| 2022-01-14 | Vogt Frederick G | Officer | A-Award | A | Restricted Stock Units | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2022-01-14 | GRAF FINCKENSTEIN FRIEDRICH | Officer | A-Award | A | Stock Option (right to buy) | 67,500 | 15.49 | 1.05M | 67,500 | — | ↗ |
| 2022-01-14 | Bellemin Jean-Marc | Officer | A-Award | A | Stock Option (right to buy) | 135,000 | 15.49 | 2.09M | 135,000 | — | ↗ |
| 2022-01-14 | BILINSKY IGOR | Officer | A-Award | A | Stock Option (right to buy) | 67,500 | 15.49 | 1.05M | 67,500 | — | ↗ |
| 2021-12-31 | MCPEAK MERRILL A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-29 | WEISER MICHAEL | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 26.33 | 921.6K | 35,000 | — | ↗ |
| 2021-06-29 | Maynard Ryan D | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 26.33 | 921.6K | 35,000 | — | ↗ |
| 2021-06-29 | MCPEAK MERRILL A | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 26.33 | 921.6K | 35,000 | — | ↗ |
| 2021-06-29 | Dukes Iain D. | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 26.33 | 1.84M | 70,000 | — | ↗ |
| 2021-06-29 | Countouriotis Athena | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 26.33 | 921.6K | 35,000 | — | ↗ |
| 2021-06-14 | Vogt Frederick G | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 23.87 | 2.39M | 100,000 | — | ↗ |
| 2021-06-14 | GRAF FINCKENSTEIN FRIEDRICH | Officer | A-Award | A | Restricted Stock Units | 39,380 | 0.00 | — | 39,380 | — | ↗ |
| 2021-06-14 | Bellemin Jean-Marc | Officer | A-Award | A | Restricted Stock Units | 37,700 | 0.00 | — | 37,700 | — | ↗ |
| 2021-06-14 | BILINSKY IGOR | Officer | A-Award | A | Restricted Stock Units | 37,700 | 0.00 | — | 37,700 | — | ↗ |
| 2021-03-15 | BILINSKY IGOR | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 34.91 | 5.24M | 150,000 | — | ↗ |
| 2021-01-04 | Vogt Frederick G | Officer | A-Award | A | Stock Option (right to buy) | 175,000 | 46.26 | 8.10M | 175,000 | — | ↗ |
| 2021-01-04 | Swartzburg Michael | Officer | A-Award | A | Stock Option (right to buy) | 45,000 | 46.26 | 2.08M | 45,000 | — | ↗ |
| 2021-01-04 | GRAF FINCKENSTEIN FRIEDRICH | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 46.26 | 4.63M | 100,000 | — | ↗ |
| 2021-01-04 | Fardis Maria | Director / Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 46.26 | 11.57M | 250,000 | — | ↗ |
| 2020-12-14 | Bellemin Jean-Marc | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 50.26 | 7.54M | 150,000 | — | ↗ |
| 2020-06-10 | Swartzburg Michael | Officer | — | D | Stock Option (Right to Buy) | 95,000 | 19.50 | 1.85M | 0 | — | ↗ |
| 2020-06-08 | WEISER MICHAEL | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 32.17 | 1.13M | 35,000 | — | ↗ |
| 2020-06-08 | Maynard Ryan D | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 32.17 | 1.13M | 35,000 | — | ↗ |
| 2020-06-08 | MCPEAK MERRILL A | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 32.17 | 1.13M | 35,000 | — | ↗ |
| 2020-06-08 | Dukes Iain D. | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 32.17 | 2.25M | 70,000 | — | ↗ |
| 2020-06-08 | Countouriotis Athena | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 32.17 | 1.13M | 35,000 | — | ↗ |
| 2020-06-01 | Fardis Maria | Director / Officer | F-InKind | D | Common Stock | 1,894 | 33.12 | 62.7K | 298,786 | — | ↗ |
| 2020-05-01 | Fardis Maria | Director / Officer | F-InKind | D | Common Stock | 1,894 | 32.00 | 60.6K | 300,680 | — | ↗ |
| 2020-04-01 | Fardis Maria | Director / Officer | F-InKind | D | Common Stock | 1,494 | 27.94 | 41.7K | 302,574 | — | ↗ |
| 2020-03-02 | Fardis Maria | Director / Officer | F-InKind | D | Common Stock | 1,321 | 35.99 | 47.5K | 304,068 | — | ↗ |
| 2020-02-03 | Fardis Maria | Director / Officer | F-InKind | D | Common Stock | 1,302 | 22.54 | 29.3K | 305,389 | — | ↗ |
| 2020-01-03 | Vogt Frederick G | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 25.54 | 3.83M | 150,000 | — | ↗ |
| 2020-01-03 | GRAF FINCKENSTEIN FRIEDRICH | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 25.54 | 1.92M | 75,000 | — | ↗ |
| 2020-01-03 | Fardis Maria | Director / Officer | A-Award | A | Stock Option (right to buy) | 500,000 | 25.54 | 12.77M | 500,000 | — | ↗ |
| 2020-01-02 | Fardis Maria | Director / Officer | F-InKind | D | Common Stock | 1,562 | 26.68 | 41.7K | 306,691 | — | ↗ |
| 2019-12-02 | Fardis Maria | Director / Officer | F-InKind | D | Common Stock | 1,894 | 22.66 | 42.9K | 308,253 | — | ↗ |
| 2019-11-01 | Fardis Maria | Director / Officer | F-InKind | D | Common Stock | 1,894 | 21.97 | 41.6K | 310,147 | — | ↗ |
| 2019-10-01 | Fardis Maria | Director / Officer | F-InKind | D | Common Stock | 1,894 | 18.21 | 34.5K | 312,041 | — | ↗ |
| 2019-09-03 | Fardis Maria | Director / Officer | F-InKind | D | Common Stock | 1,610 | 20.27 | 32.6K | 313,935 | — | ↗ |
| 2019-08-01 | Fardis Maria | Director / Officer | F-InKind | D | Common Stock | 1,321 | 25.17 | 33.2K | 315,545 | — | ↗ |
| 2019-07-18 | GRAF FINCKENSTEIN FRIEDRICH | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-07-01 | Fardis Maria | Director / Officer | F-InKind | D | Common Stock | 1,321 | 24.62 | 32.5K | 316,866 | — | ↗ |
| 2019-06-10 | WEISER MICHAEL | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 19.93 | 996.5K | 50,000 | — | ↗ |
| 2019-06-10 | Maynard Ryan D | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 19.93 | 697.6K | 35,000 | — | ↗ |
| 2019-06-10 | MCPEAK MERRILL A | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 19.93 | 697.6K | 35,000 | — | ↗ |
| 2019-06-10 | Dukes Iain D. | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 19.93 | 1.40M | 70,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-469.0K
Shares Outstanding
357.53M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Daniel Kirby Chief Commercial Officer | 507.5K | 100.0K | 1.22M | 133.8K | 184.7K | 11.8K | 2.16M | 62.79% | ↗ |
| 2 | 2025 | Frederick G. Vogt, Ph.D., J.D., Interim Chief Executive Officer and President, General Counsel | 800.0K | — | 759.4K | — | 312.0K | 16.8K | 1.89M | 40.22% | ↗ |
| 3 | 2025 | Corleen Roche Chief Financial Officer | 243.3K | 50.0K | 387.0K | 574.8K | 194.4K | 6.5K | 1.46M | 66.06% | ↗ |
| 4 | 2025 | Raj K. Puri, M.D., Ph.D. Chief Regulatory Officer | 671.9K | — | 474.6K | — | 181.4K | 13.8K | 1.34M | 35.37% | ↗ |
| 5 | 2025 | Igor Bilinsky, Ph.D., Chief Operating Officer Former Officers: | 570.5K | — | 379.7K | — | 154.0K | 13.8K | 1.12M | 33.96% | ↗ |
| 6 | 2025 | Matthew W. Rosinack Interim Principal Financial Officer and Principal Accounting Officer | 433.5K | 18.8K | 239.2K | — | 91.0K | — | 782.5K | 30.57% | ↗ |
| 7 | 2025 | Jean-Marc Bellemin, Former Chief Financial Officer | 277.5K | — | 379.7K | — | — | 6.0K | 663.1K | 57.26% | ↗ |
| 8 | 2024 | Frederick G. Vogt, Ph.D., J.D., Interim Chief Executive Officer and President, General Counsel | 730.1K | — | 9.97M | — | 237.3K | 16.8K | 10.95M | 91.02% | ↗ |
| 9 | 2024 | Friedrich Graf Finckenstein, M.D., Chief Medical Officer | 612.1K | — | 2.56M | — | 137.7K | 14.8K | 3.32M | 76.99% | ↗ |
| 10 | 2024 | Igor Bilinsky, Ph.D., Chief Operating Officer Former Officers: | 551.2K | — | 2.56M | — | 124.0K | 14.8K | 3.25M | 78.75% | ↗ |
| 11 | 2024 | Igor Bilinsky, Ph.D., Chief Operating Officer | 551.2K | — | 2.56M | — | 124.0K | 14.8K | 3.25M | 78.75% | ↗ |
| 12 | 2024 | Jean-Marc Bellemin, Former Chief Financial Officer | 551.2K | — | 2.56M | — | 124.0K | 14.8K | 3.25M | 78.75% | ↗ |
| 13 | 2024 | Jean-Marc Bellemin, Chief Financial Officer | 551.2K | — | 2.56M | — | 124.0K | 14.8K | 3.25M | 78.75% | ↗ |
| 14 | 2024 | Raj K. Puri, M.D., Ph.D. Chief Regulatory Officer | 643.0K | — | 2.38M | — | 176.2K | 14.8K | 3.22M | 74.07% | ↗ |
| 15 | 2023 | Frederick G. Vogt, Ph.D., J.D., Interim Chief Executive Officer and President, General Counsel | 692.0K | 90.0K | 890.0K | 2.48M | 629.7K | 15.2K | 4.79M | 70.24% | ↗ |
| 16 | 2023 | Friedrich Graf Finckenstein, M.D., Chief Medical Officer | 585.8K | 52.7K | 333.8K | 464.6K | 316.3K | 13.2K | 1.77M | 45.20% | ↗ |
| 17 | 2023 | Jean-Marc Bellemin, Former Chief Financial Officer | 527.5K | 47.5K | — | 836.3K | 284.9K | 13.2K | 1.71M | 48.92% | ↗ |
| 18 | 2023 | Jean-Marc Bellemin, Chief Financial Officer | 527.5K | 47.5K | — | 836.3K | 284.9K | 13.2K | 1.71M | 48.92% | ↗ |
| 19 | 2023 | Igor Bilinsky, Ph.D., Chief Operating Officer Former Officers: | 527.5K | 47.5K | 300.4K | 418.2K | 284.9K | 13.2K | 1.59M | 45.15% | ↗ |
| 20 | 2023 | Igor Bilinsky, Ph.D., Chief Operating Officer | 527.5K | 47.5K | 300.4K | 418.2K | 284.9K | 13.2K | 1.59M | 45.15% | ↗ |
| 21 | 2022 | Frederick G. Vogt, Ph.D., J.D., Interim President and Chief Executive Officer | 650.0K | 176.4K | 3.87M | — | 546.0K | 14.2K | 5.26M | 73.63% | ↗ |
| 22 | 2022 | Frederick G. Vogt, Ph.D., J.D., Interim Chief Executive Officer and President, General Counsel | 650.0K | 176.4K | 3.87M | — | 546.0K | 14.2K | 5.26M | 73.63% | ↗ |
| 23 | 2022 | Friedrich Graf Finckenstein, M.D., Chief Medical Officer | 550.0K | 188.0K | 522.8K | 627.4K | 308.0K | 12.2K | 2.21M | 52.08% | ↗ |
| 24 | 2022 | Jean-Marc Bellemin, Chief Financial Officer | 500.0K | 180.0K | — | 1.25M | 240.0K | 12.2K | 2.19M | 57.37% | ↗ |
| 25 | 2022 | Igor Bilinsky, Ph.D., Chief Operating Officer | 500.0K | 180.0K | 522.8K | 627.4K | 240.0K | 12.2K | 2.08M | 55.23% | ↗ |
| 26 | 2021 | Frederick G. Vogt, Ph.D., J.D., Interim Chief Executive Officer and President, General Counsel | 471.2K | — | — | 7.17M | 270.0K | 11.6K | 7.93M | 90.50% | ↗ |
| 27 | 2021 | Frederick G. Vogt, Ph.D., J.D., Interim President and Chief Executive Officer | 471.2K | — | — | 7.17M | 270.0K | 11.6K | 7.93M | 90.50% | ↗ |
| 28 | 2021 | Maria Fardis, Ph.D. Former President and Chief Executive Officer | 281.9K | — | — | 6.73M | — | — | 7.01M | 95.98% | ↗ |
| 29 | 2021 | Igor Bilinsky, Ph.D., Chief Operating Officer | 358.0K | 50.0K | 899.9K | 3.05M | 162.0K | 7.4K | 4.52M | 87.24% | ↗ |
| 30 | 2021 | Igor Bilinsky, Ph.D., Chief Operating Officer Former Officers: | 358.0K | 50.0K | 899.9K | 3.05M | 162.0K | 7.4K | 4.52M | 87.24% | ↗ |
| 31 | 2021 | Friedrich Graf Finckenstein, M.D., Chief Medical Officer | 468.3K | — | 940.0K | 2.69M | 169.2K | 11.6K | 4.28M | 84.84% | ↗ |
| 32 | 2021 | Jean-Marc Bellemin, Chief Financial Officer | 450.0K | — | 899.9K | — | 162.0K | 11.6K | 1.52M | 59.07% | ↗ |
| 33 | 2021 | Michael Swartzburg Former Vice President, Finance and interim Principal Accounting Officer | 65.3K | 7.00 | — | 1.21M | — | 7.3K | 1.31M | 92.19% | ↗ |
| 34 | 2020 | Maria Fardis, Ph.D. Former President and Chief Executive Officer | 600.0K | — | — | 8.14M | 300.0K | — | 9.04M | 90.04% | ↗ |
| 35 | 2020 | Maria Fardis, Ph.D. President and Chief Executive Officer | 600.0K | — | — | 8.14M | 300.0K | — | 9.04M | 90.04% | ↗ |
| 36 | 2020 | Jean-Marc Bellemin Chief Financial Officer | 450.0K | 130.0K | — | 4.42M | — | — | 5.00M | 88.40% | ↗ |
| 37 | 2020 | Jean-Marc Bellemin, Chief Financial Officer | 22.2K | 130.0K | — | 4.42M | — | — | 4.57M | 96.67% | ↗ |
| 38 | 2020 | Frederick G. Vogt, Ph.D., Esq. General Counsel and Corporate Secretary Former Officers: | 420.0K | — | — | 2.44M | 84.0K | 11.4K | 2.96M | 82.57% | ↗ |
| 39 | 2020 | Frederick G. Vogt, Ph.D., J.D., Interim President and Chief Executive Officer | 418.3K | — | — | 2.44M | 84.0K | 11.4K | 2.96M | 82.62% | ↗ |
| 40 | 2020 | Friedrich Graf Finckenstein, M.D. Chief Medical Officer | 450.0K | — | — | 1.22M | 90.0K | 11.4K | 1.77M | 68.89% | ↗ |
| 41 | 2020 | Friedrich Graf Finckenstein, M.D., Chief Medical Officer | 450.0K | — | — | 1.22M | 90.0K | 11.4K | 1.77M | 68.89% | ↗ |
| 42 | 2020 | Michael Swartzburg Former Vice President, Finance and interim Principal Financial Officer and Principal Accounting Officer | 306.2K | — | — | 707.8K | 50.5K | 11.4K | 1.08M | 65.79% | ↗ |
| 43 | 2020 | Michael Swartzburg Former Vice President, Finance and interim Principal Accounting Officer | 305.2K | — | — | 707.8K | 50.5K | 11.4K | 1.07M | 65.85% | ↗ |
| 44 | 2020 | Timothy E. Morris Former Chief Financial Officer | 242.4K | — | — | — | — | 239.7K | 482.0K | 0.00% | ↗ |
| 45 | 2019 | Maria Fardis, Ph.D. President and Chief Executive Officer | 600.0K | — | — | 2.91M | 600.0K | — | 4.11M | 70.79% | ↗ |
| 46 | 2019 | Maria Fardis, Ph.D. Former President and Chief Executive Officer | 600.0K | — | — | 2.91M | 600.0K | — | 4.11M | 70.79% | ↗ |
| 47 | 2019 | Friedrich Graf Finckenstein, M.D. Chief Medical Officer | 450.0K | 160.0K | — | 2.66M | 82.5K | 11.2K | 3.36M | 79.05% | ↗ |
| 48 | 2019 | Friedrich Graf Finckenstein, M.D., Chief Medical Officer | 204.8K | 160.0K | — | 2.66M | 82.5K | 11.2K | 3.11M | 85.28% | ↗ |
| 49 | 2019 | Frederick G. Vogt, Ph.D., Esq. General Counsel and Corporate Secretary Former Officers: | 400.0K | — | — | 1.45M | 160.0K | 11.2K | 2.03M | 71.80% | ↗ |
| 50 | 2019 | Frederick G. Vogt, Ph.D., Esq. General Counsel and Corporate Secretary | 400.0K | — | — | 1.45M | 160.0K | 11.2K | 2.03M | 71.80% | ↗ |
| 51 | 2019 | Frederick G. Vogt, Ph.D., J.D., Interim President and Chief Executive Officer | 397.9K | — | — | 1.45M | 160.0K | 11.2K | 2.02M | 71.87% | ↗ |
| 52 | 2019 | Timothy E. Morris Former Chief Financial Officer | 460.0K | — | — | 727.0K | — | 11.2K | 1.20M | 60.67% | ↗ |
| 53 | 2019 | Timothy E. Morris Chief Financial Officer | 460.0K | — | — | 727.0K | — | 11.2K | 1.20M | 60.67% | ↗ |
| 54 | 2018 | Maria Fardis, Ph.D. President and Chief Executive Officer | 600.0K | — | — | 8.28M | 510.0K | — | 9.39M | 88.18% | ↗ |
| 55 | 2018 | Timothy E. Morris Chief Financial Officer | 450.0K | — | — | — | 153.0K | 11.0K | 614.0K | 0.00% | ↗ |
| 56 | 2018 | Timothy E. Morris Former Chief Financial Officer | 450.0K | — | — | — | 153.0K | 11.0K | 614.0K | 0.00% | ↗ |
| 57 | 2018 | Timothy E. Morris Chief Financial Officer and Corporate Secretary | 450.0K | — | — | — | 153.0K | — | 603.0K | 0.00% | ↗ |
| 58 | 2018 | Frederick G. Vogt, Ph.D., Esq. General Counsel and Corporate Secretary | 375.0K | — | — | — | 127.5K | 11.0K | 513.5K | 0.00% | ↗ |
| 59 | 2018 | Frederick G. Vogt, Ph.D., Esq. General Counsel and Corporate Secretary Former Officers: | 375.0K | — | — | — | 127.5K | 11.0K | 513.5K | 0.00% | ↗ |
| 60 | 2018 | Frederick G. Vogt, Ph.D., Esq. General Counsel | 375.0K | — | — | — | 127.5K | — | 502.5K | 0.00% | ↗ |
| 61 | 2017 | Timothy E. Morris Chief Financial Officer | 172.2K | — | — | 1.26M | 65.1K | — | 1.50M | 84.18% | ↗ |
| 62 | 2017 | Timothy E. Morris Chief Financial Officer and Corporate Secretary | 172.2K | — | — | 1.26M | 65.1K | — | 1.50M | 84.18% | ↗ |
| 63 | 2017 | Frederick G. Vogt, Ph.D., Esq. General Counsel and Corporate Secretary | 326.4K | — | — | 393.1K | 131.4K | 9.1K | 859.9K | 45.71% | ↗ |
| 64 | 2017 | Frederick G. Vogt General Counsel Former Officers: | 326.4K | — | — | 393.1K | 131.4K | — | 850.8K | 46.20% | ↗ |
| 65 | 2017 | Frederick G. Vogt, Ph.D., Esq. General Counsel | 326.4K | — | — | 393.1K | 131.4K | — | 850.8K | 46.20% | ↗ |
| 66 | 2017 | Maria Fardis, Ph.D. President and Chief Executive Officer | 500.0K | — | — | — | 350.0K | — | 850.0K | 0.00% | ↗ |
| 67 | 2017 | Michael T. Lotze, M.D. Former Chief Scientific Officer | 343.6K | — | — | — | — | 109.0K | 452.6K | 0.00% | ↗ |
| 68 | 2017 | Gregory T. Schiffman Former Chief Financial Officer | 220.8K | — | — | — | — | — | 220.8K | 0.00% | ↗ |
| 69 | 2016 | Maria Fardis, Ph.D. President and Chief Executive Officer | 291.7K | — | 3.23M | 2.94M | 116.7K | 150.0K | 6.72M | 91.69% | ↗ |
| 70 | 2016 | Elma Hawkins, Ph.D. Former President and Chief Executive Officer | 325.4K | 110.0K | — | 2.72M | — | 30.0K | 3.18M | 85.39% | ↗ |
| 71 | 2016 | Gregory T. Schiffman Former Chief Financial Officer | 114.1K | — | — | 2.27M | — | 40.0K | 2.42M | 93.63% | ↗ |
| 72 | 2016 | Molly Henderson Former Chief Financial Officer | 216.9K | 93.3K | — | 1.74M | — | 350.0K | 2.40M | 72.49% | ↗ |
| 73 | 2016 | Gregory T. Schiffman Chief Financial Officer and Corporate Secretary | 114.1K | — | — | 2.23M | — | 40.0K | 2.39M | 93.54% | ↗ |
| 74 | 2016 | Steven A. Fischkoff, M.D. Chief Medical Officer | 364.5K | — | — | 1.20M | — | 100.0K | 1.67M | 72.14% | ↗ |
| 75 | 2016 | Frederick G. Vogt General Counsel Former Officers: | 75.6K | — | — | 1.51M | 13.6K | 50.0K | 1.65M | 91.56% | ↗ |
| 76 | 2016 | Frederick G. Vogt, Ph.D., Esq. General Counsel | 75.6K | — | — | 1.51M | 13.6K | 50.0K | 1.65M | 91.56% | ↗ |
| 77 | 2016 | Michael T. Lotze, M.D. Former Chief Scientific Officer | 306.4K | — | — | 1.02M | 45.7K | 116.9K | 1.49M | 68.54% | ↗ |
| 78 | 2016 | Michael T. Lotze, M.D. Chief Science Officer Former Officers: | 306.4K | — | — | 1.01M | — | 116.9K | 1.43M | 70.38% | ↗ |
| 79 | 2015 | Molly Henderson, current Chief Financial Officer | 154.2K | 40.1K | — | 2.29M | — | — | 2.49M | 92.19% | ↗ |
| 80 | 2015 | Molly Henderson Former Chief Financial Officer | 154.2K | 40.1K | — | 2.29M | — | — | 2.49M | 92.19% | ↗ |
| 81 | 2015 | Elma Hawkins, Ph.D. President and Chief Operating Officer | 400.0K | 160.0K | — | 441.5K | — | — | 1.00M | 44.08% | ↗ |
| 82 | 2015 | Elma Hawkins, Ph.D. Former President and Chief Executive Officer | 400.0K | 160.0K | — | 441.5K | — | — | 1.00M | 44.08% | ↗ |
| 83 | 2015 | James Bender, Ph.D. Vice President-Manufacturing | 216.3K | 55.7K | — | 206.9K | — | — | 478.9K | 43.20% | ↗ |
| 84 | 2015 | Laszlo Radvanyi, Ph.D. Former Chief Scientific Officer | 217.5K | — | — | — | — | — | 217.5K | 0.00% | ↗ |
| 85 | 2015 | Michael Handelman Former Chief Financial Officer | 116.1K | — | — | — | — | — | 116.1K | 0.00% | ↗ |
| 86 | 2014 | Elma Hawkins, Ph.D. President and Chief Operating Officer | 277.3K | 59.6K | 1.12M | 3.64M | — | — | 5.09M | 93.39% | ↗ |
| 87 | 2014 | Elma Hawkins, Ph.D. Former President and Chief Executive Officer | 277.3K | 59.6K | 1.12M | 3.64M | — | — | 5.09M | 93.39% | ↗ |
| 88 | 2014 | Laszlo Radvanyi, Ph.D. Former Chief Scientific Officer | 130.8K | 56.5K | 1.17M | 1.37M | — | — | 2.73M | 93.14% | ↗ |
| 89 | 2014 | James Bender, Ph.D. Vice President-Manufacturing | 207.7K | 82.5K | 959.8K | 1.25M | — | — | 2.50M | 88.39% | ↗ |
| 90 | 2014 | Michael Handelman Former Chief Financial Officer | 180.0K | 45.0K | 641.3K | 887.5K | — | — | 1.75M | 87.17% | ↗ |
| 91 | 2014 | Michael Handelman Chief Financial Officer | 180.0K | 45.0K | 641.3K | 887.5K | — | — | 1.75M | 87.17% | ↗ |
| 92 | 2014 | Manish Singh, Ph.D. former Chief Executive Officer | 350.0K | 184.0K | — | — | — | — | 534.0K | 0.00% | ↗ |
| 93 | 2013 | Michael Handelman Chief Financial Officer | 180.0K | — | — | — | — | — | 180.0K | 0.00% | ↗ |
| 94 | 2013 | Michael Handelman Former Chief Financial Officer | 180.0K | — | — | — | — | — | 180.0K | 0.00% | ↗ |
| 95 | 2013 | Michael Handelman Chief Financial Officer | 180.0K | — | — | — | — | — | 180.0K | 0.00% | ↗ |
| 96 | 2013 | Anthony Cataldo | 133.0K | — | — | — | — | — | 133.0K | 0.00% | ↗ |
| 97 | 2013 | Manish Singh, Ph.D. former Chief Executive Officer | 66.6K | — | — | — | — | — | 66.6K | 0.00% | ↗ |
| 98 | 2013 | Manish Singh, Ph.D. former Chief Executive Officer | 66.6K | — | — | — | — | — | 66.6K | 0.00% | ↗ |
| 99 | 2013 | Merrill McPeak | — | — | — | — | — | — | — | — | ↗ |
| 100 | 2012 | Michael Handelman Chief Financial Officer | 180.0K | — | — | — | — | — | 180.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Frederick G. Vogt | Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director | 1M | — |
| Raj K. Puri | Chief Regulatory Officer | 867.2K | — |
| Friedrich Graf Finckenstein | Chief Medical Officer | 764.6K | — |
| Igor Bilinsky | Chief Operating Officer | 690.1K | — |
| Elma S. Hawkins | Advisor to the Board | 465.4K | — |
| Matthew W. Rosinack | Principal Accounting Officer | — | male |
| Sara Pellegrino | Senior Vice President of Investor Relations & Corporate Communications | — | female |
| Brian Shew | Senior Vice President & Head of Digital and Information Technology | — | male |
| Tracy Winton | Executive Vice President of Human Resources | — | female |
| Corleen Roche | Chief Financial Officer | — | female |
| Howard Johnson | Chief Business Officer | — | male |
| Kevin Smyth | Executive Vice President of Quality | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IOVA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
